FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Tags >> FDA   Phase III   drug candidates   Drug Development
Syndicate content

maximize News

Most Popular maximize Story

Alpharma sells generic drug biz for $810M

Looking to streamline its operations and concentrate on developing its specialty pharmaceuticals business, Alpharma has sold its generic drug business to the Actavis Group for $810 million in cash. The sale will allow the company to pay off its debt by mid-2006.

"Alpharma's new, leaner operating profile and improved focus on specialty pharmaceuticals for both human and animal use will better position the company to improve growth and maximize shareholder value," said Alpharma CEO …

Read more...

Latest Headlines